克服基质障碍：优化胰腺癌药物递送的技术。
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer.
机构信息
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA.
出版信息
Ther Adv Med Oncol. 2012 Sep;4(5):271-9. doi: 10.1177/1758834012446008.
Abstract
Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs might be more efficient if higher levels could be achieved at the tumor site rather than the normal tissues. On the other hand, the thick stroma and the relative absence of abundant vessels may account at least partially for the failure of successive clinical trials to demonstrate effective treatments in this type of malignancy. In this context, the development and testing in clinical trials of treatment strategies that aim to optimize drug delivery is an important target in improving the prognosis of patients with pancreatic cancer.
摘要
胰腺癌在历史上已被证明对抗癌药物具有耐药性。一方面，如果在肿瘤部位而不是正常组织中能达到更高的药物浓度，药物可能会更有效。另一方面，厚实的基质和相对缺乏丰富的血管可能至少部分解释了为什么在这种类型的恶性肿瘤中，连续的临床试验未能证明有效的治疗方法。在这种情况下，旨在优化药物递送的治疗策略的开发和临床试验是改善胰腺癌患者预后的一个重要目标。
相似文献
1
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer.克服基质障碍：优化胰腺癌药物递送的技术。
Ther Adv Med Oncol. 2012 Sep;4(5):271-9. doi: 10.1177/1758834012446008.
2
T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer.T 细胞介导的抗肿瘤免疫通过 TGFβR1 拮抗和吉西他滨协同诱导，可抵抗胰腺癌基质屏障的重构。
Mol Cancer Ther. 2021 Oct;20(10):1926-1940. doi: 10.1158/1535-7163.MCT-20-0620. Epub 2021 Aug 10.
3
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.胰腺导管腺癌中的肿瘤-基质相互作用：新治疗策略的基本原理和当前证据。
Cancer Treat Rev. 2014 Feb;40(1):118-28. doi: 10.1016/j.ctrv.2013.04.004. Epub 2013 Jul 9.
4
Advances in oncolytic adenovirus therapy for pancreatic cancer.溶瘤腺病毒治疗胰腺癌的研究进展。
Cancer Lett. 2018 Oct 10;434:56-69. doi: 10.1016/j.canlet.2018.07.006. Epub 2018 Jul 5.
5
Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma.吉西他滨在接受FOLFIRINOX化疗后作为转移性胰腺腺癌二线治疗的应用。
Oncol Lett. 2017 Jun;13(6):4917-4924. doi: 10.3892/ol.2017.6061. Epub 2017 Apr 20.
6
Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.FOLFIRINOX 和吉西他滨/白蛋白紫杉醇联合序贯治疗晚期胰腺癌患者：一项单中心回顾性队列研究。
Oncol Res Treat. 2022;45(3):79-87. doi: 10.1159/000521258. Epub 2021 Dec 7.
7
Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.载有吉西他滨的自体来源外泌体用于胰腺癌的有效和安全化疗。
Acta Biomater. 2020 Jan 1;101:519-530. doi: 10.1016/j.actbio.2019.10.022. Epub 2019 Oct 18.
8
Selecting chemotherapy for pancreatic cancer: Far away or so close?选择胰腺癌化疗：远在天边还是近在咫尺？
Semin Oncol. 2019 Feb;46(1):39-47. doi: 10.1053/j.seminoncol.2018.12.004. Epub 2018 Dec 27.
9
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.白蛋白结合型紫杉醇联合吉西他滨对比白蛋白结合型紫杉醇联合吉西他滨序贯 FOLFIRINOX 诱导化疗治疗局部晚期胰腺癌（NEOLAP-AIO-PAK-0113）：一项多中心、随机、Ⅱ期临床试验。
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16.
10
Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer.剂型对治疗胰腺癌的 FOLFIRINOX 方案经离子电渗递药的影响。
Cancer Chemother Pharmacol. 2018 Jun;81(6):991-998. doi: 10.1007/s00280-018-3570-3. Epub 2018 Mar 30.
引用本文的文献
1
Extensive Review of Nanomedicine Strategies Targeting the Tumor Microenvironment in PDAC.针对胰腺癌肿瘤微环境的纳米医学策略的广泛综述
Int J Nanomedicine. 2025 Mar 17;20:3379-3406. doi: 10.2147/IJN.S504503. eCollection 2025.
2
Protease-activated CendR peptides targeting tenascin-C: mitigating off-target tissue accumulation.靶向 tenascin-C 的蛋白酶激活 CendR 肽：减轻非靶组织蓄积。
Drug Deliv Transl Res. 2024 Oct;14(10):2945-2961. doi: 10.1007/s13346-024-01670-2. Epub 2024 Jul 16.
3
Radiation-Activated Cobalamin-Kinase Inhibitors for Treatment of Pancreatic Ductal Adenocarcinoma.用于治疗胰腺导管腺癌的辐射激活型钴胺素激酶抑制剂
Mol Pharm. 2024 Jan 1;21(1):137-142. doi: 10.1021/acs.molpharmaceut.3c00667. Epub 2023 Nov 21.
4
: a promising vector for tumor immunotherapy.一种有前途的肿瘤免疫治疗载体。
Front Immunol. 2023 Oct 6;14:1278011. doi: 10.3389/fimmu.2023.1278011. eCollection 2023.
5
Bioactive Glasses as Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment.生物活性玻璃作为癌症靶向药物的载体：骨癌治疗中的挑战与机遇
Materials (Basel). 2022 Dec 19;15(24):9082. doi: 10.3390/ma15249082.
6
HPV Enhances HNSCC Chemosensitization by Inhibiting SERPINB3 Expression to Disrupt the Fanconi Anemia Pathway.人乳头瘤病毒通过抑制丝氨酸蛋白酶抑制剂B3的表达来破坏范可尼贫血途径，从而增强头颈部鳞状细胞癌的化疗敏感性。
Adv Sci (Weinh). 2022 Nov 16;10(1):e2202437. doi: 10.1002/advs.202202437.
7
Matrix stiffness mediates pancreatic cancer chemoresistance through induction of exosome hypersecretion in a cancer associated fibroblasts-tumor organoid biomimetic model.在一种癌症相关成纤维细胞-肿瘤类器官仿生模型中，基质硬度通过诱导外泌体过度分泌介导胰腺癌化疗耐药性。
Matrix Biol Plus. 2022 May 16;14:100111. doi: 10.1016/j.mbplus.2022.100111. eCollection 2022 Jun.
8
Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer.KRAS 相关代谢风险模型在胰腺癌预后预测中的建立。
Biomed Res Int. 2021 Oct 7;2021:9949272. doi: 10.1155/2021/9949272. eCollection 2021.
9
MicroRNAs in Metastasis and the Tumour Microenvironment.转移和肿瘤微环境中的微小RNA
Int J Mol Sci. 2021 May 4;22(9):4859. doi: 10.3390/ijms22094859.
10
Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.吉西他滨与成纤维细胞生长因子受体抑制剂对胰腺癌细胞周期动力学和增殖的协同药效学作用。
J Pharmacol Exp Ther. 2021 Jun;377(3):370-384. doi: 10.1124/jpet.120.000412. Epub 2021 Mar 22.
本文引用的文献
1
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.一项针对吉西他滨耐药转移性胰腺癌患者的纳米脂质体伊立替康蔗糖酯（PEP02，MM-398）的多中心 2 期研究。
Br J Cancer. 2013 Aug 20;109(4):920-5. doi: 10.1038/bjc.2013.408. Epub 2013 Jul 23.
2
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.吉西他滨联合白蛋白紫杉醇在晚期胰腺癌患者中具有活性：一项 I/II 期试验。
J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3.
3
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.FOLFIRINOX 对比吉西他滨治疗转移性胰腺癌。
N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
4
Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells.姜黄素诱导结直肠癌细胞 HCT116 产生 DNA 损伤和咖啡因不敏感的细胞周期阻滞。
Mol Cell Biochem. 2011 Aug;354(1-2):247-52. doi: 10.1007/s11010-011-0824-3. Epub 2011 Apr 28.
5
A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone.姜黄素和二十二碳六烯酸在 SK-BR-3 乳腺癌细胞中的协同抗增殖作用：独特的信号通路，无法用单一化合物的作用来解释。
BMC Cancer. 2011 Apr 21;11:149. doi: 10.1186/1471-2407-11-149.
6
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.CD40 激动剂可改变肿瘤基质，并在小鼠和人类中显示出对胰腺癌的疗效。
Science. 2011 Mar 25;331(6024):1612-6. doi: 10.1126/science.1198443.
7
A novel solubility-enhanced curcumin formulation showing stability and maintenance of anticancer activity.一种新型增溶姜黄素制剂，具有稳定性和抗癌活性。
J Pharm Sci. 2011 Jul;100(7):2778-89. doi: 10.1002/jps.22512. Epub 2011 Feb 10.
8
Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity.钙磷和聚乙二醇嵌段电荷转换聚合物负载的 siRNA 杂交纳米粒增强内涵体逃逸，实现高效基因沉默且细胞毒性可忽略。
Biomaterials. 2011 Apr;32(11):3106-14. doi: 10.1016/j.biomaterials.2010.12.057. Epub 2011 Jan 26.
9
Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.经靶向金纳米粒子治疗后，应用无创射频场破坏胰腺腺癌异种移植物。
Clin Cancer Res. 2010 Dec 1;16(23):5712-21. doi: 10.1158/1078-0432.CCR-10-2055.
10
Stromal biology and therapy in pancreatic cancer.胰腺癌的基质生物学与治疗。
Gut. 2011 Jun;60(6):861-8. doi: 10.1136/gut.2010.226092. Epub 2010 Oct 21.
Zotero 插件